The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Approval Stalls; Plus No REMS for Erythropoiesis-Stimulating Agents

Baricitinib Approval Stalls; Plus No REMS for Erythropoiesis-Stimulating Agents

April 28, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

FDA Responds to Baricitinib New Drug Application
The U.S. Food and Drug Administration (FDA) issued a complete response letter to the New Drug Application (NDA) for baricitinib, a once daily oral JAK inhibitor that is seeking approval to treat moderate to severe rheumatoid arthritis (RA). The FDA refused to approve the application in its current form, saying that additional clinical data are needed to determine the most appropriate doses. The FDA also stated that additional data are necessary to further characterize safety concerns across treatment arms.1

You Might Also Like
  • FDA Responds to New Drug Application for Baricitinib
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
Also By This Author
  • FDA Approves Celecoxib in an Oral Solution

The manufacturers, Eli Lilly and Incyte Corp., will continue to work with the FDA toward the approval of baricitinib. The manufacturers conducted four successful Phase 3 clinical trials with baricitinib as a treatment for patients with moderate to severe active RA, including the RA-BEGIN and RA-BEAM studies. The clinical trials included wide ranges of patients, such as those who were methotrexate naive and inadequate responders to methotrexate, as well as inadequate responders to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs, including TNF inhibitors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Baricitinib was approved for use in the European Union in February 2017.

No REMS for Erythropoiesis-Stimulating Agents
The erythropoiesis-stimulating agents (ESAs), epoetin alfa and darbepoetin alfa, are FDA approved for treating anemia due to chronic kidney disease, chemotherapy and HIV treatments, as well as to reduce the number of blood transfusions associated with certain major surgeries. Recently, the FDA determined that the Risk Evaluation and Mitigation Strategy (REMS) for these treatments is no longer needed for their use in patients with myelosuppressive chemotherapy-related anemia. This change will ensure that the benefits of using these ESAs outweigh their risks of shortening overall survival and/or increasing risk of tumor progression or recurrence in patients with cancer.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Eli Lilly and Company. News release: U.S. FDA issues complete response letter for baricitinib. 2017 Apr 14.
  2. U.S. Food and Drug Administration. Post-market drug safety information for patients and providers: Information on erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). 2017 Apr 13.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: baricitinib, erythropoiesis-stimulating agents (ESAs), FDA, Food and Drug Administration, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Responds to New Drug Application for Baricitinib
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
  • FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)